European Network on Optimizing Treatment With Therapeutic Antibodies in Chronic Inflammatory Diseases: Overview, Progress and Perspectives
Clinical and Translational Science · 2026-06 · 19 (6)
DOI: 10.1111/cts.70643 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Science, online erschienen am 19.06.2026. Verfasst von Konstantin Tachkov und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Organization and Economy of Pharmacy, Medical University Sofia, Sofia, Bulgaria. Hauptthemen laut MEDLINE: Inflammation, Antibodies, Monoclonal. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Treatment of chronic inflammatory diseases has been revolutionized with the introduction of targeted therapies using therapeutic antibodies. However, a large proportion of patients do not respond to treatment, or they lose response over time. To overcome this challenge, researchers have started to investigate strategies for treatment optimization, based on the development of patient stratification tools and therapeutic drug monitoring (TDM). The aim of the COST Action European Network on Optimizing Treatment with Therapeutic Antibodies in chronic inflammatory diseases (ENOTTA) is to create an interdisciplinary, pan‐European network to defragment and structure scientific research in this field. Through the network, ENOTTA will facilitate the implementation of tools for patient stratification, as well as individualized (TDM‐guided) approaches. These strategies should be cost‐effective and provide therapeutic antibody treatment optimization for the treatment of chronic inflammatory diseases. This article highlights the key achievements of the ENOTTA consortium to date.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Organization and Economy of Pharmacy, Medical University Sofia, Sofia, Bulgaria.
- Department of Biology, Faculty of Natural Sciences, University of Tirana, Tirana, Albania.
- Faculty of Medicine, University of Medicine in Tirana, Tirana, Albania.
- Versus Arthritis Centre for Genetics and Genomics, Centre for Musculoskeletal Research, the University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
- NIHR Manchester Biomedical Research Centre, Manchester Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
- University of Belgrade, Faculty of Pharmacy, Belgrade, Serbia.
ORCID-Profile: Merita Rumano, Georgios Kararigas, Paweł Kawalec, Denis Mulleman
Zitieren
APA
Tachkov, K., Rumano, M., Bluett, J., Bogavac-Stanojević, N., Dreesen, E., Itik, M., Kararigas, G., Kawalec, P., Santos, M., Skrede, S., Petrova, G., & Mulleman, D. (2026). European Network on Optimizing Treatment With Therapeutic Antibodies in Chronic Inflammatory Diseases: Overview, Progress and Perspectives. Clinical and Translational Science, 19(6). https://doi.org/10.1111/cts.70643
Vancouver
Tachkov K, Rumano M, Bluett J, Bogavac-Stanojević N, Dreesen E, Itik M, et al. European Network on Optimizing Treatment With Therapeutic Antibodies in Chronic Inflammatory Diseases: Overview, Progress and Perspectives. Clinical and Translational Science. 2026;19(6). doi:10.1111/cts.70643
BibTeX
@article{Tachkov2026,
author = {Tachkov, Konstantin and Rumano, Merita and Bluett, James and Bogavac-Stanojević, Nataša and Dreesen, Erwin and Itik, Mehmet and Kararigas, Georgios and Kawalec, Paweł and Santos, Marlene and Skrede, Silje and Petrova, Guenka and Mulleman, Denis},
title = {European Network on Optimizing Treatment With Therapeutic Antibodies in Chronic Inflammatory Diseases: Overview, Progress and Perspectives},
journal = {Clinical and Translational Science},
year = {2026},
volume = {19},
number = {6},
doi = {10.1111/cts.70643}
}
EUVIMED